Cite
HARVARD Citation
Sasaki, K. et al. (n.d.). Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leukemia & lymphoma. 56 (7), pp. 2092-2097. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Sasaki, K. et al. (n.d.). Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leukemia & lymphoma. 56 (7), pp. 2092-2097. [Online].